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background: Patients with polycystic ovary syndrome (PCOS) are at risk of arterial disease. We examined the risk of (non)fatal cor-
onary heart disease (CHD) or stroke in patients with PCOS and ovulatory women without PCOS, and assessed whether obesity might
explain a higher risk of CHD or stroke.
methods: We performed a systematic review and meta-analysis of controlled observational studies. Four deﬁnitions of PCOS were
considered: World Health Organization type II anovulation, National Institutes of Health criteria, Rotterdam consensus and Androgen-
excess criteria. Obesity was deﬁned as BMI . 30 kg/m2 and/or waist circumference .88 cm. Study quality was assessed using the
Newcastle–Ottawa Scale. Primary outcome was fatal/non-fatal CHD or stroke. Deﬁnitions of CHD and stroke were based on criteria
used by the various authors. The effect measure was the pooled relative risk in a random effects model. Risk ratios and rate ratios were
combined here.
results: After identifying 1340 articles, 5 follow-up studies published between 2000 and 2008 were included. The studies showed het-
erogeneity in design, deﬁnitions and quality. In a random effects model the relative risk for CHD or stroke were 2.02 comparing women with
PCOS to women without PCOS (95% conﬁdence interval 1.47, 2.76). Pooling the two studies with risk estimates adjusted for BMI showed a
relative risk of 1.55 (1.27, 1.89).
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conclusions: This meta-analysis showed a 2-fold risk of arterial disease for patients with PCOS relative to women without PCOS. BMI
adjustment did not affect this ﬁnding, suggesting the increased risk for cardiovascular events in PCOS is not completely related to a higher BMI
in patients with PCOS.
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Introduction
Since the publication by Stein and Leventhal (1935) on polycystic ovary
syndrome (PCOS), one biological deﬁnition [World Health Organiz-
ation (WHO) II anovulation; WHO II; WHO (1973)] and three con-
sensus deﬁnitions have been published on PCOS: National Institutes of
Health (NIH) in 1990 (Zawadski, 1992), Rotterdam in 2003 (R’dam;
Rotterdam, 2004) and Androgen-excess PCOS in 2006 (AE; Azziz
et al., 2009). In the NIH deﬁnition the symptoms hyperandrogenism
and anovulation were considered as important features of PCOS.
The Rotterdam consensus work group added polycystic ovary mor-
phology to these two criteria, whereas the Androgen-excess PCOS
criteria were the presence of hyperandrogenism (clinical and/or bio-
chemical), ovarian dysfunction (oligo-anovulation and/or polycystic
ovaries) and the exclusion of related disorders.
Apart from anovulation, increased BMI is a common feature in
women with PCOS, with a prevalence of 30–70% (Zawadski, 1992;
Azziz et al., 2004; Ehrmann, 2005; Broekmans et al., 2006; Vrbikova
and Hainer, 2009). Since the 90s of the last century an association
between PCOS and cardiovascular disease, predominantly arterial
disease, has been recognized. The American Society for Reproductive
Medicine (ASRM) Practice Committee associated PCOS with an
increased risk for cardiovascular diseases (ASRM, 2008). In a search
in PubMed (14 September 2010), 481 hits were retrieved by inserting
‘PCOS’ and the MeSH term ‘cardiovascular disease’, and 197 of these
hits were reviews. As PCOS is associated with obesity, it is still under
debate whether in PCOS the possible increased risk for cardiovascular
events (such as myocardial infarction or stroke), is merely related
to obesity. Or does PCOS per se contribute to this increased risk,
independent of obesity?
Therefore, we examined in this systematic review whether patients
with PCOS, deﬁned according to the currently used WHO (WHO,
1973), NIH (Zawadski, 1992), Rotterdam (Rotterdam, 2004) and
AE PCOS (Azziz et al., 2009) criteria, have a higher risk of fatal or non-
fatal coronary heart disease (CHD) or stroke relative to ovulatory
women without PCOS. Further, we assessed whether obesity
among patients with PCOS might explain a possible higher risk of
CHD or stroke.
Methods
Identiﬁcation of trials and eligibility criteria
Controlled studies comparing women with PCOS to women without
PCOS were considered for eligibility. We selected reports with categ-
orical data on any of the following outcomes: incident CHD and/or
stroke (non-fatal or fatal). Studies without a control group or that
did not distinguish women with or without PCOS were not included.
Comparison of PCOS to non-PCOS can only be assessed in
observational studies, thereby restricting this meta-analysis to non-
randomized studies.
For study inclusion, PCOS should have been deﬁned according to the
WHO (WHO, 1973), NIH (Zawadski, 1992), Rotterdam (Rotterdam,
2004) or AE (Azziz et al., 2009) criteria and the control group should
be PCOS-free. For the deﬁnition of obesity and waist circumference
associated with health risk, we used the criteria of the American
Medical Association (2010) and WHO (2006) for women: obesity
(.30 kg/m2) and waist circumference .88 cm (Whitlock et al., 2009).
The deﬁnition of CHD and stroke was based on the criteria used by
the various authors.
Relevant studies were identiﬁed from the Cochrane Central Register of
Controlled Trials (CENTRAL) using the keyword PCOS and cardiovascu-
lar disease. The National Center for Biotechnology Information Pubmed
database was searched for articles published before January 2010 using
any combination of the terms ‘PCOS, polycystic ovarian syndrome, adipo-
sitas, obesity, myocardial infarction, stroke, cerebrovascular accident,
cardiac disease, arterial occlusive disease, heart disease, cardiac disease’.
The EMBASE, CINAHL, POPLINE and LILACS databases were searched
in a similar fashion for additional articles. The detailed search strategy is
displayed in Appendix 1. Review articles were cross-referenced with the
results of the expanded search. Manual searches were performed of the
reference lists of selected articles. The search was not limited by language
or publication status. Data extraction was independently performed by
three investigators (P.G., S.W.M.D., F.M.H.). Disagreement was resolved
by consensus.
Quality assessment
Thequality of the included studieswas assessed according to theNewcastle–
Ottawa Scale (Higgins and Green, 2009), a validated scale for
meta-analysis of observational studies. We scored (max. nine points)
the following items important for risk of bias assessment in non-
randomized cohort studies: representativeness of the exposed cohort;
adequate selection of controls; adequate deﬁnition of the outcome
(CHD/stroke); adequacy of follow-up; comparability of exposed and non-
exposed women (two points). Low methodological quality was not an
exclusion criterion.
Data analysis
The primary outcome of the meta-analysis was the pooled risk ratio for
CHD or stroke or mortality related to CHD or stroke for women with
PCOS compared with women without PCOS. In a second analysis we cal-
culated the BMI-adjusted pooled risk ratio. Studies reporting risk ratios as
well as studies reporting rate ratios were eligible. For all studies the risk
ratio and its accompanying Standard error were extracted. On the basis
of the expected heterogeneity of the included studies we performed a
random effects model by default. Heterogeneity was calculated with the
I2 statistics. All analyses were performed with STATA 10.0, StataCorp
LP, TX, USA.
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Results
Literature search and study characteristics
The initial search (Fig. 1) yielded 1340 hits, 332 of which were dupli-
cates. A total of 996 articles were not relevant for the research ques-
tion, leaving 12 articles for detailed evaluation. In the reference list of
those 12 publications, two additional articles were identiﬁed, providing
14 articles for the current review. Nine studies were excluded for the
following reasons:
(i) surrogate endpoints for CHD (Dahlgren et al., 1992a, b; Birdsall
and Farquhar, 1997; Elting et al., 2001; Moini and Eslami, 2009),
(ii) controls were mothers of daughters with PCOS (Cheang et al.,
2008),
(iii) PCOS deﬁnition not compatible with one of the four PCOS deﬁ-
nitions of our study (WHO II, NIH, R’dam, AE) (Krentz et al.,
2007) and
(iv) double publication (Pierpoint et al., 1998; Wild et al., 2000a).
Finally, a total of ﬁve studies were included (Cibula et al., 2000; Wild
et al., 2000b; Solomon et al., 2002; Lunde and Tanbo, 2007; Shaw
et al., 2008; Table I for detailed information).
All ﬁve studies examined a cohort. All ﬁve studies used the WHO II
anovulation criterion, three the NIH (Cibula et al., 2000; Lunde and
Tanbo, 2007; Shaw et al., 2008), four the R’dam (Shaw et al., 2008;
Wild et al., 2000b; Cibula et al., 2000; Lunde and Tanbo, 2007) and
four the AE deﬁnition (Cibula et al., 2000; Wild et al., 2000b; Lunde
and Tanbo, 2007; Shaw et al., 2008). Race was mentioned by
Cibula et al. (2000) ‘all Caucasians’, by Solomon et al. (2002) ‘98%
Caucasians’ and Wild et al., (2000b) ‘99% white etnic origin’. Shaw
et al. (2008), Solomon et al. (2002) and Wild et al. (2000b) presented
data of fatal cases due to acute myocardial infarction (AMI) and stroke.
Lunde and Tanbo (2007) used hard clinical outcome of AMI, whereas
Solomon et al. (2002) included 17% probable cases of non-fatal acute
myocardial infarction/stroke in their analyses and Cibula et al. (2000)
used no hard clinical outcome of non-fatal CHD (‘chest pain evaluated
as deﬁnite or possible angina, a history of deﬁnite or possible myocar-
dial infarction, a history of transluminal percutaneous coronary angio-
plasty or coronary artery bypass grafting’). None of the ﬁve studies
presented separate data for obesity (BMI and/or waist circumference)
in the cases and controls. Four studies provided risk ratios, one study a
rate ratio.
Table II shows the assessment of methodological quality according
the Newcastle–Ottawa Scale (Higgins and Green, 2009). One study
scored seven out of nine points (Shaw et al., 2008) and one study
scored six points (Solomon et al., 2002), indicating high-quality.
Three studies scored four points or less (Cibula et al., 2000; Wild
et al., 2000b; Lunde and Tanbo, 2007), indicating low quality.
Meta-analysis
The relative risk for cardiovascular events ranged from 0.92 to 4.24.
Four of ﬁve studies showed individually a signiﬁcant increased risk for
women with PCOS. The pooled relative risk from a random effects
model was 2.02 (95% conﬁdence interval 1.47, 2.76), showing a
2-fold increased risk for CHD/stroke in women with PCOS. The
I2 showed moderate heterogeneity (42%) (Fig. 2). Two studies pro-
vided BMI-adjusted risk estimates (Wild et al., 2000b; Solomon et al.,
2002; Fig. 3). The pooled relative risk adjusted for BMI was 1.55
(95% conﬁdence interval 1.27, 1.89). In both analyses most weight
came from the Solomon study (Solomon et al., 2002) that scored
six out of nine points with the Newcastle–Ottawa Scale.
Discussion
The present meta-analysis was performed to assess the risk for
cardiovascular events in PCOS. The ﬁve included studies showed
heterogeneity in design, deﬁnitions and quality. A signiﬁcant
2-fold risk of CHD and stroke for patients with PCOS relative
to women without PCOS was found. Moreover, the risk was
still increased by 55% in the studies that adjusted for BMI. This
shows that increased BMI is not the sole cause of the increased
cardiovascular risk in women with PCOS. The largest weight in
the meta-analysis was provided by a high-quality study. In a sys-
tematic review on impaired glucose tolerance, type 2 diabetes
and metabolic syndrome in PCOS, Moran et al. (2010) recently
Figure 1 Search selection for studies on PCOS, CHD, stroke and
the inﬂuence of obesity.
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Table I Characteristics of included studies.
Author Year of
publication
Study design PCOS
deﬁnition
Participants (n) End-point Effect
measure
Relative risk
(95% CI)
Cibula et al.
(2000)
2000 Retrospective
follow-up study
WHO II, NIH,
R’dam, AE
PCOS 28, Controls
752
Non-fatal CHD and
stroke
Risk ratio 4.24 (1.96,
9.17)
Lunde and
Tanbo (2007)
2007 Retrospective
follow-up study
WHO II, NIH,
R’dam, AE
PCOS 131, Controls
723
Non-fatal CHD Risk ratio 0.92
Shaw et al.
(2008)
2008 Prospective
follow-up study
WHO II, NIH,
R’dam, AE
PCOS 104, Controls
286
Fatal + non-fatal
CHD and stroke
Hazard ratio 2.3 (1.4, 3.8)
Solomon et al.
(2002)
2002 Prospective
follow-up study
WHO II PCOS 49 292a,
Control 715 293
Fatal + non-fatal
CHD and stroke
Rate ratio 1.67 (1.35,
2.06)
Wild et al.
(2000b)
2000 Retrospective
follow-up study
WHO II, AE,
R’dam
PCOS 319, Control
1060
Non-fatal CHD and
stroke
Odds ratio 1.9 (1.1, 3.3)
PCOS, polycystic ovary syndrome; CHD, coronary heart disease; CI, conﬁdence interval; WHO, World Health Organization; NIH, National Institutes of Health; R’dam, Rotterdam;
AE, Androgen-excess PCOS.
aPerson years.
.............................................................................................................................................................................................
Table II Assessment of methodological quality (based on Newcastle–Ottawa Scale).
Exposed
cohort
representative
Adequate
control
selection
Adequate
end-point
deﬁnition
Outcome
unknown
from start
Matched
or adj.
analysis
(Comp.)a
Hard
clinical
outcome
Follow-up
in patients
>60 years
Adequate
follow-up
Total
Cibula et al.
(2000)
0 0 1 0 0 0 0 0 1
Lunde and
Tanbo (2007)
0 0 1 0 1 1 0 1 4
Shaw et al.
(2008)
0 1 1 1 1 1 1 1 7
Solomon
et al. (2002)
1 1 1 1 1 1 0 0 6
Wild et al.
(2000b)
1 0 1 1 1 0 0 0 4
aComparability: two points.
Figure 2 Meta-analysis of ﬁve cohort studies on the risk of CHD and stroke in PCOS. ES, effect size.
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found that women with PCOS had increased prevalence of
impaired glucose tolerance, type 2 diabetes in both BMI and
non-BMI-matched studies.
This meta-analysis has several limitations. First, the deﬁnitions of
PCOS used were not identical for all studies. Whereas anovulation
is a characteristic of all deﬁnitions, it could not be estimated from
the data whether the speciﬁc features of the other PCOS deﬁnitions
(NIH, Rotterdam and AE) compared with the WHO anovulation
have an effect on this risk. Second, hard clinical outcome data were
not always used and separate data for coronary disease and stroke
were not available in all ﬁve studies.
What are the implications of the results? We have shown that
PCOS is associated with an increased cardiovascular risk. However,
we are far from causality as formulated by Hill (1965) and various
important questions remain to be investigated. Although increased
BMI was not the sole cause of the increased risk for cardiovascular
events, the role of BMI should be investigated in more detail in pro-
spective studies. It is an open question whether the other distinguish-
ing features of PCOS, such as hyperandrogenism, are causing the risk
excess (Jovanovic et al., 2010). A possible interference of infertility and
of fertility treatments for patients with anovulation—the most explicit
feature of ovarian dysfunction—on their arterial health might be
involved.
Implications for practice
Our study showed that PCOS should be considered as a risk factor for
cardiovascular disease; importantly, this risk is partially independent of
BMI. Nevertheless, weight reduction remains an important aim of
treatment in overweight patients with PCOS.
Implications for research
(i) Conduct observational studies according to STROBE guidelines
(von Elm et al., 2007),
(ii) use internationally accepted and clinically relevant deﬁnitions,
(iii) use hard clinical endpoints.
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Appendix 1: Search methods for
identiﬁcation of studies
Search strategies
EMBASE database search strategy
(Exp polycystic ovary syndrome/OR (((pco or pcos or pcod) AND
(ovary or ovarian or ovaria)) OR polycystic ovary syndrome* OR poly-
cystic ovarian syndrome* OR cystic ovary OR micropolycystic ovary
OR micropolycystic ovaries OR multiple follicle cyst OR ovary poly-
cystic syndrome OR polycystic ovarian disease OR polycystic ovary
OR polycystic ovaries OR polycystic ovary disease OR polycystic
ovary syndrome).mp) AND (Stroke/OR Exp heart diseases/OR
(Myocardial infarct* or stroke or cerebrovascular accident* or heart
infarct* or heart disease* or cardiac disease*).mp OR exp peripheral
occlusive artery disease/OR Cerebrovascular accident/OR (arterial
disease* OR artery diseas*).mp OR (heart OR myocardial OR
cardiac OR cerebrovascular OR arterial OR coronary).ti).
NCBI-pubmed database search strategy
(((pco[tw] OR pcos[tw] OR pcod[tw]) AND (ovary[tw] OR ovar-
ian[tw] OR ovarial[tw] OR ovaries[tw])) OR polycystic ovary syn-
drome OR polycystic ovary syndrome*[tw] OR polycystic ovarian
syndrome OR cystic ovary OR micropolycystic ovary OR micropo-
lycystic ovaries OR multiple follicle cyst OR ovary polycystic syn-
drome OR polycystic ovarian disease OR polycystic ovary OR
polycystic ovaries OR polycystic ovary disease OR polycystic
ovary syndrome) AND (myocardial infarction OR “stroke”[Text
word] OR “stroke”[MeSH Terms] OR cerebrovascular accident*[-
Text Word] OR “heart diseases”[MeSH Terms] OR heart disea-
se*[Text Word] OR cardiac disease*[tw] OR “Arterial Occlusive
Diseases”[Mesh] OR heart[ti] OR myocardial[ti] OR cardiac[ti]
OR cerebrovascular[ti] OR arterial[ti] OR coronary[ti] OR “arterial
disease” OR “arterial diseases” OR “artery disease” OR “artery
diseases”).
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